Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeremy Millar

Showing results (91-100 of 103) with videos related to

Pageof 11
Sort By:
BMJ Open|August 9, 2024
Impact of the diagnostic label for a low-risk prostate lesion: protocol for two online factorial randomised experimentsJames Bullen, Brooke Nickel, Kirsten McCaffery, et al.
International Journal of Radiation Oncology, Biology, Physics|October 6, 2023
Long-Term Quality-of-Life Outcomes After Prostate Radiation Therapy With or Without High-Dose-Rate Brachytherapy Boost: Post Hoc Analysis of TROG 03.04 RADARWee Loon Ong, John Nikitas, David Joseph, et al.
The Lancet. Oncology|May 9, 2016
Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trialGillian M Duchesne, Henry H Woo, Julie K Bassett, et al.
BJUI Compass|July 22, 2025
A population-based analyses of the evolving management of cN1M0 prostate cancer in the PSMA-PET eraJennifer Ward, Kevin Armstrong, Therese Min-Jung Kang, et al.
International Journal of Radiation Oncology, Biology, Physics|December 27, 2023
Prostate-Specific Antigen Response to Androgen Deprivation Therapy in the Neoadjuvant Setting for High-Risk Prostate Adenocarcinoma (PIRANHA): Pooled Analysis of Two Randomized Clinical TrialsJohn Nikitas, Wee Loon Ong, Nathalie Carrier, et al.
Journal of the National Cancer Institute|June 14, 2025
Association of non-steroidal anti-inflammatory medications and aspirin with colorectal cancer incidence in older adultsFarzana Y Zaman, Suzanne G Orchard, Galina Polekhina, et al.
The Lancet. Oncology|May 8, 2007
Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trialDavid P Dearnaley, Matthew R Sydes, John D Graham, et al.
BJU International|June 5, 2014
A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy -- Adjuvant Versus Early Salvage (RAVES) trialMaria Pearse, Carol Fraser-Browne, Ian D Davis, et al.
BMJ Open|August 23, 2019
TROG 18.01 phase III randomised clinical trial of the Novel Integration of New prostate radiation schedules with adJuvant Androgen deprivation: NINJA study protocolJarad Martin, Paul Keall, Shankar Siva, et al.
BJU International|January 14, 2012
Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study GroupPeter Grimm, Ignace Billiet, David Bostwick, et al.
Pageof 11

Showing results (91-100 of 103) with videos related to

Sort By:
Pageof 11
BMJ Open|August 9, 2024
Impact of the diagnostic label for a low-risk prostate lesion: protocol for two online factorial randomised experimentsJames Bullen, Brooke Nickel, Kirsten McCaffery, et al.
International Journal of Radiation Oncology, Biology, Physics|October 6, 2023
Long-Term Quality-of-Life Outcomes After Prostate Radiation Therapy With or Without High-Dose-Rate Brachytherapy Boost: Post Hoc Analysis of TROG 03.04 RADARWee Loon Ong, John Nikitas, David Joseph, et al.
The Lancet. Oncology|May 9, 2016
Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trialGillian M Duchesne, Henry H Woo, Julie K Bassett, et al.
BJUI Compass|July 22, 2025
A population-based analyses of the evolving management of cN1M0 prostate cancer in the PSMA-PET eraJennifer Ward, Kevin Armstrong, Therese Min-Jung Kang, et al.
International Journal of Radiation Oncology, Biology, Physics|December 27, 2023
Prostate-Specific Antigen Response to Androgen Deprivation Therapy in the Neoadjuvant Setting for High-Risk Prostate Adenocarcinoma (PIRANHA): Pooled Analysis of Two Randomized Clinical TrialsJohn Nikitas, Wee Loon Ong, Nathalie Carrier, et al.
Journal of the National Cancer Institute|June 14, 2025
Association of non-steroidal anti-inflammatory medications and aspirin with colorectal cancer incidence in older adultsFarzana Y Zaman, Suzanne G Orchard, Galina Polekhina, et al.
The Lancet. Oncology|May 8, 2007
Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trialDavid P Dearnaley, Matthew R Sydes, John D Graham, et al.
BJU International|June 5, 2014
A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy -- Adjuvant Versus Early Salvage (RAVES) trialMaria Pearse, Carol Fraser-Browne, Ian D Davis, et al.
BMJ Open|August 23, 2019
TROG 18.01 phase III randomised clinical trial of the Novel Integration of New prostate radiation schedules with adJuvant Androgen deprivation: NINJA study protocolJarad Martin, Paul Keall, Shankar Siva, et al.
BJU International|January 14, 2012
Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study GroupPeter Grimm, Ignace Billiet, David Bostwick, et al.
Pageof 11